Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Omics-Based Clinical Trials Market Growth From $34.48 Billion In 2026 To $47.77 Billion By 2030 At A CAGR Of 8.5%
The market for omics-based clinical trials has experienced significant expansion recently. Projections indicate a rise from $31.71 billion in 2025 to $34.49 billion in 2026, reflecting a compound annual growth rate of 8.8%. Factors fueling this historical growth include the escalating intricacy of clinical trial methodologies, advancements in genomic and proteomic investigations, a mounting need for tailored medical treatments, the broadening of clinical research facilities, and enhanced partnerships between pharmaceutical companies and academic bodies.
The omics-based clinical trials market demonstrates a trajectory of robust expansion, projected to reach a valuation of $47.78 billion by 2030. This impressive growth is underpinned by a compound annual growth rate of 8.5% over the forecast period, fueled by several key drivers. These include the escalating embrace of personalized medicine strategies, a surge in financial commitment towards data-centric clinical trial methodologies, the broadened application of AI-powered patient recruitment solutions, increasing validation of omics-derived endpoints by regulatory bodies, and a heightened need for optimizing clinical trial results. Furthermore, significant developments anticipated within this timeframe encompass a greater reliance on biomarker-guided trial frameworks, more extensive utilization of multi-omics data for patient segmentation, the deeper incorporation of real-world evidence analysis, a widened scope for precision oncology trials, and a more pronounced concentration on optimizing trials through data-focused approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp
Omics-Based Clinical Trials Market Demand Drivers Creating New Revenue Opportunities
The burgeoning field of personalized medicine is set to significantly fuel the expansion of the omics-based clinical trials sector. This approach to healthcare customizes disease prevention, diagnosis, and treatment based on a patient’s unique biological makeup. Such a shift towards individualized care is largely driven by advancements in genomic technologies, which now facilitate rapid and affordable examination of genetic information, paving the way for precisely targeted therapies. Omics-based clinical trials are instrumental in realizing personalized medicine’s potential by facilitating the detailed profiling of an individual’s genes, proteins, and metabolic pathways, thereby enabling the development of highly effective and patient-specific treatment plans. Illustrating this trend, the Personalized Medicine Coalition reported that in 2023, the US Food and Drug Administration authorized 16 novel personalized treatments for individuals with rare diseases, a notable increase from the six such approvals granted in 2022; these 2023 authorizations also included seven cancer therapies and three treatments for other conditions. Consequently, the growing need for personalized medicine directly stimulates the growth trajectory of the omics-based clinical trials market.
Omics-Based Clinical Trials Market Segment Analysis And Revenue Opportunities
The omics-based clinical trials market covered in this report is segmented –
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
Omics-Based Clinical Trials Market Trends Driving Strategic Industry Expansion
Businesses leading the charge in the omics-driven clinical trials sector are prioritizing novel approaches, including the adoption of HiFi sequencing technology, with the goal of boosting the precision, rapidity, and comprehensiveness of multi-omics data interpretation, thereby refining clinical trial results and tailoring therapeutic interventions. HiFi sequencing represents a sophisticated next-generation sequencing (NGS) methodology that generates extensive, exceptionally accurate readings through circular consensus sequencing (CCS), thereby facilitating a thorough and exact examination of genomic, transcriptomic, and epigenomic data. As a prime example, in October 2024, Pacific Biosciences of California Inc., an American biotech firm, partnered with Singapore’s Agency for Science, Technology, and Research (A*STAR) and South Korea’s Macrogen Inc. to inaugurate a premier laboratory in Singapore, leveraging advanced long-read sequencing capabilities to expedite genomic advancements. This facility empowers researchers to undertake sophisticated genomic investigations with enhanced accuracy and efficiency, catering to diverse applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics, while also cultivating international and local scientific partnerships to speed up breakthroughs in personalized medicine, rare disease identification, and precision oncology, complemented by training initiatives and shared access to high-capacity sequencing resources to build expertise and foster innovation across the Asia-Pacific region.
Omics-Based Clinical Trials Market Leading Players Shaping Industry Direction
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.
Access The Complete Omics-Based Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
Omics-Based Clinical Trials Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the omics-based clinical trials market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model